{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:54:41Z","timestamp":1793915681125,"version":"4.8.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    Myasthenia gravis (MG) appears to have a similar incidence among adult populations worldwide. However, epidemiological and phenotypic differences have been noted among children and juveniles with MG. We reviewed the literature on childhood- and juvenile-onset MG among different populations, with the focus on ocular involvement, antibody profiles, the genetic susceptibility to juvenile MG phenotypes, the use of immune treatments, and the reported responses of extraocular muscles to therapies. Although epidemiological studies used different methodologies, reports from Asia, compared to Europe, showed more than two-fold higher proportions of prepubertal onset (before 12 years) vs. postpubertal-onset juveniles with MG. Compared to European children, ocular MG was 4-fold more frequent among Asian children, and 2\u20133-fold more frequent among children with African ancestry both in prepubertal and postpubertal ages at onset. These results suggest genetic influences. In Asia,\n                    <jats:italic>HLA-B<\/jats:italic>\n                    <jats:sup>*<\/jats:sup>\n                    <jats:italic>46<\/jats:italic>\n                    and\n                    <jats:italic>DRB1<\/jats:italic>\n                    <jats:sup>*<\/jats:sup>\n                    <jats:italic>09<\/jats:italic>\n                    appeared overrepresented in children with ocular MG. In Europe, children with MG had a significantly higher rate of transforming from ocular to generalized disease and with an overrepresentation of\n                    <jats:italic>HLADRB1<\/jats:italic>\n                    <jats:sup>*<\/jats:sup>\n                    <jats:italic>04<\/jats:italic>\n                    . Although treatment regimens vary widely and the responses to immune therapies of the ocular muscles involved in MG were generally poorly described, there were indications that earlier use of steroid therapy may have better outcomes. Reports of treatment-resistant ophthalmoplegia may be more frequent in African and Asian juvenile MG cohorts compared to Europeans. Genetic and muscle gene expression studies point to dysregulated muscle atrophy signaling and mitochondrial metabolism pathways as pathogenetic mechanisms underpinning treatment-resistant ophthalmoplegia in susceptible individuals. In conclusion, phenotypic differences in juveniles with ocular manifestations of MG were evident in different populations suggesting pathogenetic influences. Treatment responses in MG-associated ocular disease should attract more careful descriptive reports. In MG, extraocular muscles may be vulnerable to critical periods of poor force generation and certain individuals may be particularly susceptible to developing treatment-resistant ophthalmoplegia. The development of prognostic biomarkers to identify these susceptible individuals is an unmet need.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2022.834212","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T06:37:19Z","timestamp":1645598239000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review"],"prefix":"10.3389","volume":"13","author":[{"given":"Jeannine M.","family":"Heckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarin A.","family":"Europa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayesha J.","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1196\/annals.1405.037","article-title":"Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?","volume":"1132","author":"Soltys","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3389\/fgene.2019.00136","article-title":"Using whole genome sequencing in an african subphenotype of myasthenia gravis to generate a pathogenetic hypothesis","volume":"10","author":"Nel","year":"2019","journal-title":"Front Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.nmd.2020.02.001","article-title":"ENMC workshop study group","volume":"30","author":"Munot","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J Neurol Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00415-015-7638-2","article-title":"Long-term outcome of 424 childhood-onset myasthenia gravis patients","volume":"262","author":"Gui","year":"2015","journal-title":"J Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10072-012-1159-x","article-title":"The high frequency and clinical feature of seronegative myasthenia gravis in Southern China","volume":"34","author":"Feng","year":"2013","journal-title":"Neurol Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/0883073816666206","article-title":"'Juvenile Myasthenia Gravis in Korea: Subgroup Analysis According to Sex and Onset Age","volume":"31","author":"Lee","year":"2016","journal-title":"J Child Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s10072-013-1329-5","article-title":"A cohort study on myasthenia gravis patients in China","volume":"34","author":"Wang","year":"2013","journal-title":"Neurol Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/mus.26745","article-title":"Response to treatment in pediatric ocular myasthenia gravis","volume":"61","author":"Xu","year":"2020","journal-title":"Muscle Nerve."},{"key":"B10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mus.25965","article-title":"Clinical features and evolution of juvenile myasthenia gravis in a French cohort","volume":"57","author":"Barraud","year":"2018","journal-title":"Muscle Nerve."},{"key":"B11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.7196\/SAMJ.5390","article-title":"The characteristics of juvenile myasthenia gravis among South Africans","volume":"102","author":"Heckmann","year":"2012","journal-title":"S Afr Med J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.1542\/peds.2013-0814","article-title":"Clinical characteristics of pediatric myasthenia: a surveillance study","volume":"132","author":"VanderPluym","year":"2013","journal-title":"Pediatrics."},{"key":"B13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0960-8966(98)00077-7","article-title":"Juvenile myasthenia gravis with prepubertal onset","volume":"8","author":"Evoli","year":"1998","journal-title":"Neuromuscul Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ejpn.2017.04.003","article-title":"Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, long-term outcome in a nationwide population-based cohort","volume":"21","author":"Popperud","year":"2017","journal-title":"Eur J Paediatr Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/mus.26445","article-title":"Treatment outcome in juvenile-onset myasthenia gravis","volume":"59","author":"Jastrzebska","year":"2019","journal-title":"Muscle Nerve."},{"key":"B16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1600-0404.1992.tb08056.x","article-title":"Myasthenia gravis in Hong Kong Chinese","volume":"86","author":"Wong","year":"1992","journal-title":"Pediatric disease Acta Neurol Scand"},{"key":"B17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12883-019-1397-0","article-title":"Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study","volume":"19","author":"Chou","year":"2019","journal-title":"BMC Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0404.2006.00646.x","article-title":"Myasthenia gravis in children: a longitudinal study","volume":"114","author":"Ashraf","year":"2006","journal-title":"Acta Neurol Scand."},{"key":"B19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ajo.2019.01.004","article-title":"Incidence and ocular features of pediatric myasthenias","volume":"200","author":"Mansukhani","year":"2019","journal-title":"Am J Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.nmd.2019.11.008","article-title":"Pediatric myasthenia gravis: Prognostic factors for drug free remission","volume":"30","author":"Vecchio","year":"2020","journal-title":"Neuromuscul Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/01.wnl.0000176067.32186.a3","article-title":"Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis","volume":"65","author":"Somnier","year":"2005","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000311012","article-title":"Nationwide population-based epidemiological study of myasthenia gravis in Taiwan","volume":"35","author":"Lai","year":"2010","journal-title":"Neuroepidemiology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/jnnp.2008.152637","article-title":"Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan","volume":"80","author":"Matsui","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/mus.24348","article-title":"Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa","volume":"51","author":"Mombaur","year":"2015","journal-title":"Muscle. Nerve."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/j.1468-1331.2012.03698.x","article-title":"A national epidemiological study of Myasthenia Gravis in Australia","volume":"19","author":"Gattellari","year":"2012","journal-title":"Eur J Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.ejpn.2017.07.011","article-title":"Juvenile myasthenia gravis","volume":"21","author":"Heckmann","year":"2017","journal-title":"Eur J Paediatr Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10072-012-1157-z","article-title":"Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years","volume":"34","author":"Huang","year":"2013","journal-title":"Neurol Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fneur.2018.00077","article-title":"Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China","volume":"9","author":"Huang","year":"2018","journal-title":"Front Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pediatrneurol.2018.06.007","article-title":"Juvenile ocular myasthenia gravis: presentation and outcome of a large cohort","volume":"87","author":"Vanikieti","year":"2018","journal-title":"Pediatr Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1212\/WNL.44.7.1208","article-title":"Race, sex, puberty influence onset, severity, outcome in juvenile myasthenia gravis","volume":"44","author":"Andrews","year":"1994","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"577403","DOI":"10.1016\/j.jneuroim.2020.577403","article-title":"Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays","volume":"349","author":"Yan","year":"2020","journal-title":"J Neuroimmunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ejpn.2016.09.001","article-title":"Juvenile myasthenia gravis in Norway: A nationwide epidemiological study","volume":"21","author":"Popperud","year":"2017","journal-title":"Eur J Paediatr Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/archdischild-2013-304788","article-title":"How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia","volume":"99","author":"Parr","year":"2014","journal-title":"Arch Dis Child."},{"key":"B34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/mus.21195","article-title":"Juvenile myasthenia gravis","volume":"39","author":"Chiang","year":"2009","journal-title":"Muscle Nerve."},{"key":"B35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/jnnp.2006.102517","article-title":"Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands","volume":"78","author":"Niks","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/practneurol-2012-000404","article-title":"Congenital myasthenic syndromes: an update","volume":"13","author":"Finlayson","year":"2013","journal-title":"Pract Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/15569520701830992","article-title":"The pattern of extra-ocular muscle involvement in ocular myasthenia","volume":"16","author":"Cleary","year":"2008","journal-title":"Strabismus."},{"key":"B38","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/mus.26172","article-title":"Myasthenic ophthalmoparesis: Time To resolution after initiating immune therapies","volume":"58","author":"Europa","year":"2018","journal-title":"Muscle Nerve."},{"key":"B39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/nyas.13471","article-title":"unique subphenotype of myasthenia gravis","volume":"1412","author":"Heckmann","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/S0161-6420(03)00460-3","article-title":"Childhood ocular myasthenia gravis","volume":"110","author":"Kim","year":"2003","journal-title":"Ophthalmology."},{"key":"B41","first-page":"883","article-title":"Treatment Outcomes and Predictive Factors in Pediatric Ocular Myasthenia Gravis","volume":"98","author":"Kraithat","year":"2015","journal-title":"J Med Assoc Thai."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ophtha.2007.10.022","article-title":"Long-term outcomes of pediatric ocular myasthenia gravis","volume":"115","author":"Ortiz","year":"2007","journal-title":"Ophthalmology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Task Force Med Scientific Advis Board Myasthenia Gravis Found Am Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","article-title":"Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment","volume":"89","author":"Kupersmith","year":"2005","journal-title":"Br J Ophthalmol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"single- blinded trial of methotrexate vs. azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12969-018-0255-8","article-title":"Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting","volume":"16","author":"Ferrara","year":"2018","journal-title":"Pediatr Rheumatol Online J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13023-019-1025-5","article-title":"Congenital myasthenic syndromes","volume":"14","author":"Finsterer","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.nmd.2007.07.002","article-title":"Myasthenia gravis in South Africans: racial differences in clinical manifestations","volume":"17","author":"Heckmann","year":"2007","journal-title":"Neuromuscul Disord."},{"key":"B49","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0161-6420(99)00138-4","article-title":"The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children","volume":"107","author":"Mullaney","year":"2000","journal-title":"Ophthalmology."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/mus.25154","article-title":"Characteristics Of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort","volume":"54","author":"Huda","year":"2016","journal-title":"Muscle Nerve"},{"key":"B51","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/bjo.2006.108498","article-title":"Ocular myasthenia: a rare presentation with MuSK antibody and bilateral extraocular muscle atrophy'","volume":"91","author":"Chan","year":"2007","journal-title":"Br J Ophthalmol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s00234-021-02753-4","article-title":"evidence of extraocular muscle atrophy and fatty replacement in myasthenia gravis","volume":"63","author":"Velonakis","year":"2021","journal-title":"Neuroradiology."},{"key":"B53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mus.26114","article-title":"Burden of illness in patients with treatment refractory myasthenia gravis","volume":"58","author":"Engel-Nitz","year":"2018","journal-title":"Muscle Nerve."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s00415-019-09667-5","article-title":"Frequency and clinical features of treatment-refractory myasthenia gravis","volume":"267","author":"Rath","year":"2020","journal-title":"J Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/brain\/103.3.579","article-title":"Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis","volume":"103","author":"Compston","year":"1980","journal-title":"Brain."},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-73585-6_5","article-title":"Epidemiology and genetics of myasthenia gravis","volume-title":"Myasthenia Gravis and Related Disorders","author":"Nel","year":"2018"},{"key":"B57","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1172\/JCI114724","article-title":"antigens in Japanese patients with myasthenia gravis","volume":"86","author":"Matsuki","year":"1990","journal-title":"J Clin Invest."},{"key":"B58","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1749-6632.1993.tb22947.x","article-title":"haplotype in myasthenia gravis (MG) of Japanese children. correlative studies between mg patients and their normal siblings and parents","volume":"681","author":"Nomura","year":"1993","journal-title":"Ann N Y Acad Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/jnnp.56.4.382","article-title":"Association of HLA-Bw46DR9 combination with juvenile myasthenia gravis in Chinese","volume":"56","author":"Chen","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B60","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/oxfordjournals.qjmed.a068318","article-title":"Possible evidence for a variant of myasthenia gravis based on HLA and acetylcholine receptor antibody in Chinese patients","volume":"70","author":"Hawkins BR Yu","year":"1989","journal-title":"Q J Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e0186383","DOI":"10.1371\/journal.pone.0186383","article-title":"Juvenile myasthenia gravis in Norway: HLA-DRB1*04:04 is positively associated with prepubertal onset","volume":"12","author":"Popperud","year":"2017","journal-title":"PLoS One."},{"key":"B62","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clim.2003.10.004","article-title":"A variant of childhood-onset myasthenia gravis: HLA typing and clinical characteristics in Japan","volume":"110","year":"2004","journal-title":"Clin Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jneuroim.2012.03.018","article-title":"HLA-DQA1*03:02\/DQB1*03:03:02 is strongly associated with susceptibility to childhood-onset ocular myasthenia gravis in Southern Han Chinese","volume":"247","author":"Zhu","year":"2012","journal-title":"J Neuroimmunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10072-015-2235-9","article-title":"The HLA-B*4601\u2013 DRB1*0901 haplotype is positively correlated with juvenile ocular myasthenia gravis in a southern Chinese Han population","volume":"36","author":"Feng","year":"2015","journal-title":"Neurol Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.nmd.2017.06.009","article-title":"Exome sequencing identifies targets in the treatment-resistant ophthalmoplegic subphenotype of myasthenia gravis","volume":"27","author":"Nel","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"B66","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/WNO.0000000000000534","article-title":"Extraocular muscle findings in myasthenia gravis associated treatment-resistant ophthalmoplegia","volume":"37","author":"Rautenbach","year":"2017","journal-title":"J Neuroophthalmol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.nmd.2019.03.009","article-title":"A review of the histopathological findings in myasthenia gravis: Clues to the pathogenesis of treatment-resistance in extraocular muscles Neuromuscul Disord","volume":"29","author":"Europa","year":"2019"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1002\/nbm.4407","article-title":"The feasibility of quantitative MRI of extra-ocular muscles in myasthenia gravis and Graves' orbitopathy","volume":"20","author":"Keene","year":"2020","journal-title":"NMR Biomed."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2147\/OPTH.S280508","article-title":"Radiological characteristics of extraocular muscles in myasthenia gravis patients with ocular manifestations: a case-control study","volume":"15","author":"Lueangaram","year":"2021","journal-title":"Clin Ophthalmol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fphys.2016.00524","article-title":"Differential RNA expression profile of skeletal muscle induced by experimental autoimmune myasthenia gravis in rats","volume":"7","author":"Kaminski","year":"2016","journal-title":"Front Physiol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00424-005-0010-0","article-title":"Lactate is a metabolic substrate that sustains extraocular muscle function","volume":"452","author":"Andrade","year":"2006","journal-title":"Pflugers Arch."},{"key":"B72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.nmd.2004.10.002","article-title":"Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders","volume":"15","author":"Wai","year":"2005","journal-title":"Neuromuscul Disord."},{"key":"B73","doi-asserted-by":"publisher","first-page":"11230","DOI":"10.1038\/s41598-020-68185-x","article-title":"AChR antibodies show a complex interaction with human skeletal muscle cells in a transcriptomic study","volume":"10","author":"Hong","year":"2020","journal-title":"Sci Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/gene.2009.61","article-title":"functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis","volume":"11","author":"Heckmann","year":"2010","journal-title":"Genes Immun."},{"key":"B75","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/jhg.2015.146","article-title":"The African-387 C>T TGFB1 variant is functional and associates with the ophthalmoplegic complication in juvenile myasthenia gravis","volume":"61","author":"Nel","year":"2016","journal-title":"J Hum Genet."},{"key":"B76","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13023-020-01629-9","article-title":"Gene expression profiling of orbital muscles in treatment-resistant ophthalmoplegic myasthenia gravis","volume":"15","author":"Europa","year":"2020","journal-title":"Orphanet J Rare Dis."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.834212\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T06:37:24Z","timestamp":1645598244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.834212\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":76,"alternative-id":["10.3389\/fneur.2022.834212"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.834212","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"article-number":"834212"}}